NOTE
🌱 created from: majestec-1
covid-19_and_majestec-1
- Design: Phase 1/2 clinical trial, multi-center, open-label
- Number of patients: 165
- Patients characteristics: Patients with relapsed/refractory multiple myeloma
- Agent: Teclistamab 1.5 mg/kg weekly
- Treatment line: Patients received teclistamab as treatment
- Trial Acronym/NCTId Number: NCT03145181/NCT04557098
- Compare efficacy:
| Parameter | Result |
|---|---|
| Infections | 80.0% |
| Grade 3/4 infections | 55.2% |
| COVID-19 | 21.2% |
| Neutropenia | 65.5% |
- Highlight of toxicity: Grade 3/4 infections occurred in 55.2% of patients, including COVID-19 and respiratory infections.
- One-line summary: Teclistamab treatment in patients with relapsed/refractory multiple myeloma led to a high rate of infections, including COVID-19, highlighting the importance of monitoring and management of infections during treatment.
Nooka AK, Rodriguez C, Mateos MV, et al. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study. Cancer. 2024;130(6):886-900. doi:10.1002/cncr.35107